Treatment of cynomolgus monkeys with low doses of this IL‐2 mutein protein allowed for a sustained 10‐ to 14‐fold increase in CD4+ and CD8+ Tregs, which opens up possibility for using IL‐2 therapy to treat autoimmune diseases. Here, CD8A is linked to autoimmune disease.